Clinical Updates in Psoriatic Arthritis


The Rheumatology Network psoriatic arthritis clinical focus page provides information on the latest psoriatic arthritis news, study and clinical trial findings, and clinical guideline updates. We feature expert interviews with leading physicians and investigators, articles, videos, podcasts, and breaking FDA approvals for psoriatic arthritis drugs.

Guselkumab Sustained Long-Term Efficacy in Patients with Active Psoriatic Arthritis

March 18, 2021

Guselkumab is the first and only approved IL-23 inhibitor therapy used to treat adults with active PsA and moderate to severe plaque psoriasis (PsO). The medication showed efficacy in skin clearance and joint symptom relief and passed safety measures. Additionally, physical function, health-related quality of life, and resolution of enthesitis and dactylitis were confirmed through week 100.

Q&A: Diagnostic Delay in Psoriatic Arthritis

March 18, 2021

The diagnosis of psoriatic arthritis (PsA) may be delayed by more than 2 years in half of patients, especially those of younger age at symptom onset, or with a higher body mass index (BMI) or enthesitis before diagnosis.

Upadacitinib Shows Efficiency in Psoriatic Arthritis Refractory to Biologics

March 08, 2021

In patients with psoriatic arthritis refractory or intolerant to biologic disease-modifying antirheumatic drugs (DMARDs), upadacitinib (Abbvie; Rinvoq) 15 mg and 30 mg once per day was more effective than placebo over 24 weeks in improving signs and symptoms of psoriatic arthritis.

Ixekizumab Shows Benefit in Patients With Psoriatic Arthritis and Inadequate TNFi Response

February 23, 2021

Generally, guidelines recommend beginning psoriatic arthritis (PsA) treatment with tumor necrosis factor inhibitors (TNFis). However, not all patients respond to this method. Ixekizumab (IXE) improved the signs and symptoms of PsA in patients who had exhibited inadequate response to 1 or 2 TNFis.

Etanercept Shows Greater Improvements in Treating Psoriatic Arthritis Than MTX Monotherapy

February 05, 2021

In this 48-week, phase 3, randomized controlled trial, investigators examined patient-reported outcomes of patients with psoriatic arthritis receiving methotrexate monotherapy, etanercept monotherapy, or a combination of both drugs.

TNF Inhibitor Use in Psoriatic Arthritis Does Not Increase Solid Cancer Risk

January 27, 2021

Investigators determined, “Treatment with TNF inhibitors is not associated with increased risks of solid cancer overall, or eight common cancer types. There were no indications of different crude incidence of solid cancers overall by TNF inhibitor agent.”

If Remission Is Our Goal, Rheumatology Must Embrace the Importance of Studying New Mechanisms

January 25, 2021

Alyssa Johnsen, MD, PhD, shares her insight on the importance of understanding key pathways that drive immune-mediated diseases, which can help rheumatologists develop more potent and specific therapies for patients with rheumatic disease.

Secukinumab Improves Axial Disease in Psoriatic Arthritis

January 21, 2021

Improvement in ASAS20 (Assessment of SpondyloArthritis international Society) was seen in 63% of participants assigned to secukinumab 300 mg and 66% of those assigned to secukinumab 150 mg, versus 31% of the placebo group.

Long-Term Ixekizumab Versus Adalimumab in Psoriatic Arthritis

November 10, 2020

In patients with psoriatic arthritis who are DMARD naïve, ixekizumab had similar efficacy at one year whether it was used as a monotherapy or in combination with methotrexate or csDMARD, while adalimumab showed better efficacy as a combination therapy.

Guselkumab Reduces Fatigue in Psoriatic Arthritis Patients

November 06, 2020

In a study that examined the effects of guselkumab (Tremfya, Janssen) on fatigue in patients with psoriatic arthritis, the treatment reduced fatigue through one year, according to researchers reporting at the annual meeting of the American College of Rheumatology on Friday.

Secukinumab Not Associated With Tuberculosis

October 02, 2020

Researchers writing in JAMA Dermatology report that latent tuberculosis infection previously assumed to be an adverse event as a result of treatment with secukinumab, is actually uncommon in patients with chronic systemic inflammatory conditions.